Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
bladder/antikancerogeno
Veza se sprema u međuspremnik
Stranica 1 iz 167 rezultatima
Continuous Bladder Irrigation Following Transurethral Resection of Bladder Tumors
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Bladder tumor recurrence after resection of non-muscle invasive bladder cancer (NMIBC) occurs in 50-70% of patients despite the use of adjuvant anticancer therapy after surgery. This is a single-arm, non-randomized pilot study looking to determine whether post-Transurethral Resection of Bladder
Autophagy Bladder Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
- In Egypt, Bladder Cancer is the most prevalent malignancy among Egyptian males (16%) producing more than 7900 deaths annually . The majority of patients with bladder cancer about (70-80%) present with non-muscle invasive bladder cancer .
- Autophagy is a highly conserved catabolic process that
Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Patient-reported Outcomes in Bladder Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Bladder cancer is in Europe the 4th most incident cancer among men and the 7th most frequent cause of cancer death. Many patients will receive chemo- or immunotherapy in either the neoadjuvant setting or for recurrent or metastatic disease. The registration and handling of side effect is crucial in
Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Patients who are treated with bacillus Calmette-Guerin (BCG) intravesical therapy for non-muscle invasive (TaT1) Tis superficial bladder cancer often develop adverse effects (urinary tract symptoms) which limit the dose (and therefore the efficacy) of therapy and result in poor quality of life.
CIK in Treating Patients With Bladder Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
About 1500 patients with staging I-III of Bladder Cancer, after accepting chemotherapy, will be randomly divided into group A (receive CIK treatment) or group B (just regularly follow up), and the randomize ratio will be 1:1. Patients in group A will receive 3 cycles of CIK cells treatment (every 12
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.
The FDA (the U.S. Food and Drug
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Therapy background
For intermediate/high risk NMIBC clinical guidelines recommend as standard therapy complete transurethral resection of the bladder tumor (s) (TURB), followed by immunotherapy with six weekly intravesical instillations of approx. 5x10E8 CFUs of Bacillus Calmette Guérin (BCG) and
Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
OBJECTIVES:
- To assess the effect of lifestyle factors (e.g., smoking, dietary habits, fluid intake, or environmental exposures) on the recurrence and progression of bladder cancer.
- To assess the impact of selenium and/or vitamin E on the progression and recurrence of bladder cancer.
- To study
Gene Therapy in Treating Patients With Advanced Bladder Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
PRIMARY OBJECTIVES:
I. Determine the safety and toxicity of adenovirus p53 (Ad-p53) gene therapy in patients with locally advanced or metastatic bladder cancer.
II. Measure infection with Ad-p53 and confirm expression of p53 after infection.
III. Characterize clinical response of measurable tumor in
Onco4D(TM) Biodynamic Chemotherapy Selection for Bladder Cancer Patients
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
STUDY RATIONALE: The demonstrated ability of MCT to accurately assess tumor xenografts may establish it as a reliable technique for patient tumor stratification based on predicted response to therapy, which could enable a treatment selection based on the personal needs of an individual patient. This
Health-Related Quality of Life in Patients With Bladder Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
OBJECTIVES:
- To identify aspects of survivorship experience that differ by clinical risk (low risk vs high risk) in patients with non-invasive bladder cancer.
- To collect and examine data on health-related quality of life (HRQOL) and symptom management.
- To analyze differences in outcomes between
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
The rationale of the present study is to develop a combination based on the pharmacokinetics and mechanisms of action of the agents paclitaxel plus gemcitabine and cisplatin, which are all known active agents in urothelial tumors. Gemcitabine may be synergistic with DNA-damaging drugs such as
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
PRIMARY OBJECTIVE:
I. To characterize the safety profile of pembrolizumab in patients with urothelial carcinoma undergoing radical cystectomy.
SECONDARY OBJECTIVES:
I. To explore a signal of anti-cancer immunological activity by evaluating surgical specimens for evidence of post-treatment
Najkompletnija baza ljekovitog bilja potpomognuta znanošću
- Radi na 55 jezika
- Biljni lijekovi potpomognuti znanošću
- Prepoznavanje bilja slikom
- Interaktivna GPS karta - označite bilje na mjestu (uskoro)
- Pročitajte znanstvene publikacije povezane s vašom pretragom
- Pretražite ljekovito bilje po učincima
- Organizirajte svoje interese i budite u toku s istraživanjem vijesti, kliničkim ispitivanjima i patentima
Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Svi podaci temelje se na objavljenim znanstvenim istraživanjima
